Our sites in Colomiers and Gannat (France) are regularly inspected by ANSM (France) and by ANVISA (Brazil) and the Russian Federation, as well as other international authorities.
Our sites are regularly inspected by Chinese health authorities, the FDA (United States), ANVISA (Brazil), etc.
Unither is particularly relevant for projects requiring high flexibility, small batch sizes, and specialized expertise, such as:
early-stage development
clinical batches (Phase I–III)
niche or low-volume commercial products
complex formulations (e.g. hormonal or highly viscous semi-solids)
This makes Unither a strong partner for innovative, rare disease or lifecycle management projects.
Unither supports a wide range of dosage forms, including:
tablets and capsules
powders and granules
gels, creams and ointments
suppositories and pessaries
Each formulation is developed to ensure stability, performance and regulatory compliance.
Unither offers specific know-how in semi-solid and suppository manufacturing, including:
handling of highly viscous formulations
expertise in hormonal and non-hormonal drugs
dedicated equipment and processes
These forms are particularly relevant for pediatric use, local treatments (e.g. hemorrhoids), or patients unable to take oral medication.
Yes. Through its Bordeaux R&D center, Unither specializes in small batch manufacturing, covering:
This flexibility, combined with expertise in complex formulations, makes Unither particularly well suited for orphan drugs, rare diseases, repositioned molecules and targeted therapies.
Supported by integrated analytical and regulatory capabilities, this approach enables you to move efficiently from early development to first commercial supply, without requiring large-scale production from the outset, and helps accelerate time-to-market for specialized treatments.
